Central Nervous System Therapeutics Market Size, Share, Trends, & Industry Analysis Report, By Disease (Neurovascular Disease, CNS Trauma, Mental Health), By Drug Class, By Distribution Channel, and By Region – Market Forecast, 2025–2034
Description
The central nervous system therapeutics market size is expected to reach USD 265.54 Billion by 2034, according to a new study by Polaris Market Research. The report “Central Nervous System Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease (Neurovascular Disease, CNS Trauma, Mental Health), By Drug Class, By Distribution Channel, and By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Central Nervous System (CNS) therapeutics refers to treatments aimed at managing and alleviating disorders affecting the brain, spinal cord, and nerves, such as depression, epilepsy, Parkinson’s disease, and Alzheimer’s. These therapies include medications, biologics, and emerging digital and precision medicine approaches designed to improve neurological function and quality of life.
An aging population is one of the strongest drivers of the CNS therapeutics market. People become more prone to neurological and mental health conditions like Alzheimer’s, Parkinson’s, and dementia as people age. These age-related disorders are chronic and progressive, requiring long-term medical attention and treatment. The rise in the elderly population globally in region such as North America, Europe, and parts of Asia is putting pressure on healthcare systems to provide better and more efficient CNS care. Older adults are also more likely to seek medical help and adhere to treatment plans, driving consistent demand for CNS drugs and therapies. In response, pharmaceutical companies are focusing their research efforts on neurodegenerative conditions and age-related cognitive decline. Governments are further increasing funding for elderly healthcare programs, including those targeting CNS disorders. The need for effective, accessible, and safe CNS therapeutics rise as the global senior population continues to grow, thereby driving the growth.
The post-COVID-19 landscape has redefined healthcare priorities, placing greater emphasis on mental well-being and neurological care. The pandemic not only highlighted the vulnerabilities in accessing CNS treatments during health crises but also increased demand for digital therapeutics, remote care models, and innovative approaches to managing chronic neurological conditions. Governments and private organizations are also investing more into CNS research, driven by the growing burden of neurodegenerative and psychiatric illnesses, thereby driving the growth.
Central Nervous System Therapeutics Market Report Highlights
The mental health segment accounted for 26.15% share during the forecast period driven by a global rise in psychiatric conditions such as depression, anxiety, bipolar disorder, and schizophrenia.
The hospital pharmacy segment accounted USD 55.43 billion revenue in 2024 as many CNS treatments, especially for severe mental health or neurovascular conditions, are administered or initiated in hospital settings under close medical supervision.
North America central nervous system therapeutics market accounted for 40.24% global market share in 2024 driven by advanced healthcare infrastructure, high healthcare spending, and widespread awareness of neurological and mental health conditions.
The Asia Pacific central nervous system therapeutics market recorded USD 25.12 billion revenue in 2024, due to its large population, rising healthcare investment, and increasing awareness of neurological disorders.
The global key market players are AstraZeneca plc; Biogen Inc.; Eli Lilly and Company; Johnson & Johnson; Merck & Co., Inc.; Neuraxpharm; Novartis AG; Otsuka Pharmaceutical Co., Ltd; Pfizer Inc.; Takeda Pharma Company Ltd; Teva Pharmaceutical Industries Ltd.
Polaris market research has segmented the central nervous system therapeutics market report based on Disease, drug class, distribution channel, and region:
By Disease (Revenue - USD Billion, 2020–2034)
Neurovascular Diseases
CNS Trauma
Mental Health
Neurodegenerative Diseases
Alzheimer’s Disease
Parkinson's Disease
Multiple Sclerosis
Huntington’s Disease
Amyotrophic Lateral Sclerosis
Others
Infectious Diseases
CNS Cancer
Others
By Drug Class (Revenue - USD Billion, 2020–2034)
Anesthetics
Anticonvulsants
Antiemetic
CNS Stimulants
Pain Relievers
Others
By Distribution Channel (Revenue - USD Billion, 2020–2034)
Hospital Pharmacy
Retail Pharmacy
Other
By Regional Outlook (Revenue - USD Billion, 2020–2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of APAC
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of MEA
Central Nervous System (CNS) therapeutics refers to treatments aimed at managing and alleviating disorders affecting the brain, spinal cord, and nerves, such as depression, epilepsy, Parkinson’s disease, and Alzheimer’s. These therapies include medications, biologics, and emerging digital and precision medicine approaches designed to improve neurological function and quality of life.
An aging population is one of the strongest drivers of the CNS therapeutics market. People become more prone to neurological and mental health conditions like Alzheimer’s, Parkinson’s, and dementia as people age. These age-related disorders are chronic and progressive, requiring long-term medical attention and treatment. The rise in the elderly population globally in region such as North America, Europe, and parts of Asia is putting pressure on healthcare systems to provide better and more efficient CNS care. Older adults are also more likely to seek medical help and adhere to treatment plans, driving consistent demand for CNS drugs and therapies. In response, pharmaceutical companies are focusing their research efforts on neurodegenerative conditions and age-related cognitive decline. Governments are further increasing funding for elderly healthcare programs, including those targeting CNS disorders. The need for effective, accessible, and safe CNS therapeutics rise as the global senior population continues to grow, thereby driving the growth.
The post-COVID-19 landscape has redefined healthcare priorities, placing greater emphasis on mental well-being and neurological care. The pandemic not only highlighted the vulnerabilities in accessing CNS treatments during health crises but also increased demand for digital therapeutics, remote care models, and innovative approaches to managing chronic neurological conditions. Governments and private organizations are also investing more into CNS research, driven by the growing burden of neurodegenerative and psychiatric illnesses, thereby driving the growth.
Central Nervous System Therapeutics Market Report Highlights
The mental health segment accounted for 26.15% share during the forecast period driven by a global rise in psychiatric conditions such as depression, anxiety, bipolar disorder, and schizophrenia.
The hospital pharmacy segment accounted USD 55.43 billion revenue in 2024 as many CNS treatments, especially for severe mental health or neurovascular conditions, are administered or initiated in hospital settings under close medical supervision.
North America central nervous system therapeutics market accounted for 40.24% global market share in 2024 driven by advanced healthcare infrastructure, high healthcare spending, and widespread awareness of neurological and mental health conditions.
The Asia Pacific central nervous system therapeutics market recorded USD 25.12 billion revenue in 2024, due to its large population, rising healthcare investment, and increasing awareness of neurological disorders.
The global key market players are AstraZeneca plc; Biogen Inc.; Eli Lilly and Company; Johnson & Johnson; Merck & Co., Inc.; Neuraxpharm; Novartis AG; Otsuka Pharmaceutical Co., Ltd; Pfizer Inc.; Takeda Pharma Company Ltd; Teva Pharmaceutical Industries Ltd.
Polaris market research has segmented the central nervous system therapeutics market report based on Disease, drug class, distribution channel, and region:
By Disease (Revenue - USD Billion, 2020–2034)
Neurovascular Diseases
CNS Trauma
Mental Health
Neurodegenerative Diseases
Alzheimer’s Disease
Parkinson's Disease
Multiple Sclerosis
Huntington’s Disease
Amyotrophic Lateral Sclerosis
Others
Infectious Diseases
CNS Cancer
Others
By Drug Class (Revenue - USD Billion, 2020–2034)
Anesthetics
Anticonvulsants
Antiemetic
CNS Stimulants
Pain Relievers
Others
By Distribution Channel (Revenue - USD Billion, 2020–2034)
Hospital Pharmacy
Retail Pharmacy
Other
By Regional Outlook (Revenue - USD Billion, 2020–2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of APAC
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of MEA
Table of Contents
125 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
